Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00263614 · ClinicalTrials.gov registry record
Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.
A clinical trial of Chronic Hepatitis B, sponsored by Gilead Sciences.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT00263614: Completed study of Chronic Hepatitis B, sponsored by Gilead Sciences.
NCT00263614 is a study of Chronic Hepatitis B that has completed, run by Gilead Sciences. The registered enrollment target is 100 participants, below the 287-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00263614, a study of Chronic Hepatitis B, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether HBeAg-positive and HBeAg-negative patients with HBV DNA greater than or less than 5 log10 and 4 log10 copies/mL, respectively, and with normal or minimally elevated liver transaminases have histological evidence of active liver disease.
Conditions Studied
Study Locations (1)
California
- Gilead Sciences, Inc. - Foster City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-06 |
What the finished NCT00263614 record still lists
NCT00263614 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 287-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 0 interventions.
NCT00263614 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00263614 about?
NCT00263614 is a clinical study titled "Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.". To determine whether HBeAg-positive and HBeAg-negative patients with HBV DNA greater than or less than 5 log10 and 4 log10 copies/mL, respectively, and with normal or minimally elevated liver transaminases have histological evidence of active liver disease.
What is the current status of trial NCT00263614?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2005-12. Estimated completion is 2007-06.
What conditions does trial NCT00263614 study?
This clinical trial studies the following conditions: Chronic Hepatitis B.
Who is sponsoring clinical trial NCT00263614?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00263614 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00263614's enrollment target sits among peer trials
100 9th of 14 higher than 6 of 14 other Chronic Hepatitis B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Hepatitis B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
RECRUITING · Phase 2
-
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
RECRUITING · Phase 2
-
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
RECRUITING · Phase 2
-
TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
RECRUITING · Phase 1
-
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia